as 05-17-2024 4:00pm EST
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.
Founded: | 2017 | Country: | United States |
Employees: | N/A | City: | BETHESDA |
Market Cap: | 45.9M | IPO Year: | 2021 |
Target Price: | $8.50 | AVG Volume (30 days): | 122.4K |
Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.50 | EPS Growth: | N/A |
52 Week Low/High: | $2.00 - $5.33 | Next Earning Date: | 05-14-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | 2025.77% | Revenue Growth (next year): | -65.22% |
GANX Breaking Stock News: Dive into GANX Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
Zacks
16 days ago
GlobeNewswire
25 days ago
Zacks
a month ago
Insider Monkey
a month ago
Zacks
a month ago
Zacks
a month ago
GlobeNewswire
a month ago